Chrysin mitigated obesity by regulating energy intake and expenditure in rats

10.1016/j.jtcme.2019.09.002

Sarayu A. Pai；Elvis Adrian Martis；Renuka P. Munshi；Malvika S. Gursahani；Snehal N. Mestry；Archana R. Juvekar

Adipose tissue ； Locomotion ； Pancreatic lipase ； Sucrose preference

Journal of Traditional and Complementary Medicine

10卷6期（2020 / 11 / 01）

577 - 585

英文

Background and aim: Chrysin is a flavonoid found in plant extracts from Passiflora species, honey and propolis. It has demonstrated anti-adipogenic activity in vitro but there are no studies substantiating the anti-obesity activity of chrysin in vivo. Experimental procedure: The pancreatic lipase (PL) inhibitory potential of chrysin was determined by preliminary in silico screening and further confirmed by in vitro PL inhibitory assay and oral fat tolerance test (OFTT). The effect of chrysin on acute feed intake and sucrose preference test was determined in normal rats. Obesity was induced by feeding of high fructose diet (HFD) to the rats. The rats were divided into six groups: normal control, HFD control, orlistat and three doses of chrysin (25, 50 and 100 mg/kg body weight). Body weight, body mass index (BMI), abdominal circumference/thoracic circumference (AC/TC) ratio, calorie intake, adiposity index, fecal cholesterol, locomotor activity and histopathology of the adipose tissue of the rats were evaluated. Results: Chrysin showed good affinity to PL with competitive type of inhibition. It significantly reduced serum triglycerides in OFTT. Chrysin also significantly reduced acute feed intake and sucrose preference in rats. Chrysin significantly decreased the body weight, BMI, AC/TC ratio, adiposity index, calorie intake while it significantly increased the fecal cholesterol and locomotor activity of the rats. Chrysin was found to reduce the size of the adipocytes when compared to the HFD control group. Conclusion: Thus, chrysin exerted anti-obesity effect by inhibiting PL, reducing sucrose preference, reducing calorie intake and increasing the locomotor activity of rats.

1. Bellamkonda, R,Karuna, R,SasiBhusana Rao, B(2017).Beneficial effect of Commiphora mukul ethanolic extract against high fructose diet induced abnormalities in carbohydrate and lipid metabolism in Wistar rats.J Tradit Complement Med,8(1),203-211.
   連結：
2. Kim, H,Wang, Q,Shoemaker, CF,Zhong, F,Bartley, GE,Yokoyama, WH(2014).Polysaccharide gel coating of the leaves of Brasenia schreberi lowers plasma cholesterol in hamsters.J Tradit Complement Med,5(1),56-61.
   連結：
3. Intralipid® 20%. Available at https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/017643s072,018449s039lbl.pdf. Accessed 21st March 2019.
4. Andrade, N,Andrade, S,Silva, C(2019).Chronic consumption of the dietary polyphenol chrysin attenuates metabolic disease in fructose-fed rats.Eur J Nutr
5. Avena, NM,Bocarsly, ME,Murray, S,Gold, MS(2014).Effects of baclofen and naltrexone, alone and in combination, on the consumption of palatable food in male rats.Exp Clin Psychopharmacol,22(5),460-467.
6. Buchholz, T,Melzig, MF(2015).Polyphenolic compounds as pancreatic lipase inhibitors.Planta Med,81(10),771-783.
7. Bueter, M,Miras, AD,Chichger, H(2011).Alterations of sucrose preference after Roux-en-Y gastric bypass.Physiol Behav,104(5),709-721.
8. Chin, SH,Kahathuduwa, CN,Binks, M(2016).Physical activity and obesity: what we know and what we need to know.Obes Rev.,17(12),1226-1244.
9. Choi, JH,Yun, JW(2016).Chrysin induces brown fat-like phenotype and enhances lipid metabolism in 3T3-L1 adipocytes.Nutrition,32(9),1002-1010.
10. Coulter, AA,Rebello, CJ,Greenway, FL(2018).Centrally acting agents for obesity: Past, present, and future.Drugs,78(11),1113-1132.
11. Egloff, MP,Marguet, F,Buono, G,Verger, R,Cambillau, C,van Tilbeurgh, H(1995).The 2.46 A resolution structure of the pancreatic lipase-colipase complex inhibited by a C11 alkyl phosphonate.Biochemistry,34(9),2751-2762.
12. Engin, A(2017).The pathogenesis of obesity-associated adipose tissue inflammation.Adv Exp Med Biol,960,221-245.
13. Farkhondeh, T,Abedi, F,Samarghandian, S(2019).Chrysin attenuates inflammatory and metabolic disorder indices in aged male rat.Biomed Pharmacother,109,1120-1125.
14. Feng, X,Qin, H,Shi, Q(2014).Chrysin attenuates inflammation by regulating M1/M2 status via activating PPARg.Biochem Pharmacol,89(4),503-514.
15. Folch, J,Lees, M,Sloane Stanley, GH.(1957).A simple method for the isolation and purification of total lipids from animal tissues.J Biol Chem,226(1),497-509.
16. Friesner, RA,Banks, JL,Murphy, RB(2004).Glide: a new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy.J Med Chem,47(7),1739-1749.
17. Gad, SC,Cassidy, CD,Aubert, N,Spainhour, B,Robbe, H(2006).Nonclinical vehicle use in studies by multiple routes in multiple species.Int J Toxicol,25(6),499-521.
18. Golozoubova, V,Strauss, F,Malmlof, K(2006).Locomotion is the major determinant of sibutramine induced increase in energy expenditure.Pharmacol Biochem Behav,83(4),517-527.
19. Heymsfield, SB,Wadden, TA(2017).Mechanisms, pathophysiology and management of obesity.N Engl J Med.,376(3),254-266.
20. Kakkar, AK,Dahiya, N(2015).Drug treatment of obesity: current status and future prospects.Eur J Intern Med.,26(2),89-94.
21. Kalhotra, P,Chittepu, VCSR,Osorio-Revilla, G,Gallardo-Velázquez, T(2018).Structure-activity relationship and molecular docking of natural product library reveal chrysin as a novel dipeptidyl peptidase-4 inhibitor: an integrated in silico and in vitro study.Molecules,23(6),1368.
22. Kazmi, I,Afzal, M,Rahman, S,Iqbal, M,Imam, F,Anwar, F(2013).Antiobesity potential of ursolic acid stearoyl glucoside by inhibiting pancreatic lipase.Eur J Pharmacol,709(1-3),28-36.
23. Kenny, PJ(2011).Reward mechanisms in obesity: new insights and future directions.Neuron,69(4),664-679.
24. Lindqvist, A,Baelemans, A,Erlanson-Albertsson, C(2008).Effects of sucrose, glucose and fructose on peripheral and central appetite signals.Regul Pept,150(1-3),26-32.
25. Lunagariya, NA,Patel, NK,Jagtap, SC,Bhutani, KK(2014).Inhibitors of pancreatic lipase: state of the art and clinical perspectives.EXCLI J.,13,897-921.
26. Mangal, P,Khare, P,Jagtap, S,Bishnoi, M,Kondepudi, KK,Bhutani, KK(2017).Screening of six Ayurvedic medicinal plants for anti-obesity potential: an investigation on bioactive constituents from Oroxylum indicum (L.) Kurz bark.J Ethnopharmacol,197,138-146.
27. Mani, R,Natesan, V(2018).Chrysin: sources, beneficial pharmacological activities, and molecular mechanism of action.Phytochemistry,145,187-196.
28. Marranzano, M,Ray, S,Godos, J,Galvano, F(2018).Association between dietary flavonoids intake and obesity in a cohort of adults living in the Mediterranean area.Int J Food Sci Nutr,69(8),1020-1029.
29. Narayanaswami, V,Dwoskin, LP(2017).Obesity: current and potential pharmaco-therapeutics and targets.Pharmacol Ther,170,116-147.
30. Pai, SA,Martis, EAF,Joshi, SG,Munshi, RP,Juvekar, AR(2018).Plumbagin exerts anti-obesity effects through inhibition of pancreatic lipase and adipocyte differentiation.Phytother Res,32(8),1631-1635.
31. Pai, SA,Munshi, RP,Panchal, FH(2019).Plumbagin reduces obesity and nonalcoholic fatty liver disease induced by fructose in rats through regulation of lipid metabolism, inflammation and oxidative stress.Biomed Pharmacother,111,686-694.
32. Pascual-Serrano, A,Arola-Arnal, A,Suarez-Garcia, S(2017).Grapeseed proanthocyanidin supplementation reduces adipocyte size and increases adipocyte number in obese rats.Int J Obes.,41(8),1246-1255.
33. Prunet-Marcassus, B,Desbazeille, M,Bros, A(2003).Melatonin reduces body weight gain in Sprague Dawley rats 484 with diet-induced obesity.Endocrinology,144(12),5347-5352.
34. Pushpavalli, G,Kalaiarasi, P,Veeramani, C,Pugalendi, KV(2010).Effect of chrysin on hepatoprotective and antioxidant status in D-galactosamine-induced hepatitis in rats.Eur J Pharmacol,631(1-3),36-41.
35. Razavi, BM,Lookian, F,Hosseinzadeh, H(2017).Protective effects of green tea on olanzapine-induced metabolic syndrome in rats.Biomed Pharmacother,92,726-731.
36. Stenkula, KG,Erlanson-Albertsson, C(2018).Adipose cell size: importance in health and disease.Am J Physiol Regul Integr Comp Physiol,315(2),R284-R295.
37. Stice, E,Figlewicz, DP,Gosnell, BA,Levine, AS,Pratt, WE(2013).The contribution of brain reward circuits to the obesity epidemic.Neurosci Biobehav Rev,37(9 Pt A),2047-2058.
38. Taha, SA,Norsted, E,Lee, LS(2006).Endogenous opioids encode relative taste preference.Eur J Neurosci.,24(4),1220-1226.
39. Tappy, L(2018).Fructose-containing caloric sweeteners as a cause of obesity and metabolic disorders.J Exp Biol,221(Pt suppl 1)
40. Tulloch, AJ,Murray, S,Vaicekonyte, R,Avena, NM(2015).Neural responses to macronutrients: hedonic and homeostatic mechanisms.Gastroenterology,148(6),1205-1218.
41. Vickers, SP,Jackson, HC,Cheetham, SC(2011).The utility of animal models to evaluate novel anti-obesity agents.Br J Pharmacol,164(4),1248-1262.
42. Wang, Y,Wang, J,Yanagita, RC(2014).Effects of two sulfated triterpene saponins echinoside A and holothurin A on the inhibition of dietary fat absorption and obesity reduction.Biosci Biotechnol Biochem,78(1),139-146.
43. Yimam, M,Jiao, P,Hong, M(2016).Appetite suppression and antiobesity effect of a botanical composition composed of Morus alba, Yerba mate and Magnolia officinalis.J Obes.,2016,4670818.